Archives
-
Bedaquiline: Mechanism, Evidence, and Workflows
2026-09-29
Bedaquiline is a diarylquinoline antibiotic that disrupts Mycobacterium tuberculosis energy production through F1FO-ATP synthase inhibition. Its reported mitochondrial and glycolytic effects also support controlled cancer stem cell and metabolism research, while the cited evidence does not establish clinical oncology use.
-
BglII Restriction Endonuclease: Practical Workflow
2026-09-28
BglII Restriction Endonuclease provides rapid cleavage of DNA containing the 5′-AGATCT-3′ recognition site, supporting plasmid DNA digestion, PCR product cleavage, and selected genomic DNA workflows. It should be used when the target sequence and expected digest pattern are known, and it is not intended for diagnostic or medical applications.
-
DiscoveryProbe Stem Cell Compound Library Plus
2026-09-28
Use pathway-focused chemical perturbations to ask how muscle satellite cells balance proliferation, differentiation, and self-renewal—not simply whether cells survive. This guide connects the ASB5 marker study to a practical, control-rich screening workflow using the 280-compound DiscoveryProbe collection.
-
High-Content Screening of Schistosome Stem Cells
2026-09-27
Perera, Chioni and Walker developed an imaging-based platform to quantify dividing neoblasts in developmentally advanced Schistosoma mansoni schistosomula, then used it to prioritize compounds that impaired parasite development and stem-cell proliferation. The study offers a more quantitative route for anti-schistosome screening while highlighting the need to confirm candidate activity across parasite stages and with independent readouts.
-
IL-15 Assays and the Next Neuroimmune Questions
2026-09-26
Early-life adversity research illustrates how precise mechanistic studies can reveal deficits in innate defensive behavior without establishing an immune cause. This article examines what the findings mean for translational research, where Recombinant Human IL-15 can support carefully bounded immune assays, and how to design reproducible studies without overclaiming a neuroimmune link.
-
MitMAB in Polarity-Aware EV Uptake Assays
2026-09-25
MitMAB offers a target-directed way to test dynamin dependence in extracellular-vesicle uptake experiments. This article connects polarity-aware intestinal stem cell models with practical assay design and explains why inhibitor-sensitive uptake is evidence of pathway involvement—not proof of a complete internalization mechanism.
-
Mc-Val-Cit-PABC-PNP: ADC Linker Workflow Guide
2026-09-25
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable ADC peptide linker for research workflows designed to release payload after lysosomal processing. Its strong DMSO solubility supports organic-solvent handling, but it is insoluble in water and ethanol and is not intended for diagnostic, clinical, or therapeutic use.
-
PPT (Propyl Pyrazole Triol) in ERα Research
2026-09-24
Use PPT to activate ERα selectively and test whether estrogen receptor signaling contributes to a candidate gene response. A practical workflow connects dose-controlled cell experiments with a female lung adenocarcinoma hypothesis—without treating that hypothesis as proof of a cancer mechanism.
-
RAB31 Defines an ESCRT-Independent Exosome Route
2026-09-24
The study identifies RAB31 as a regulator of an exosome pathway that bypasses canonical ESCRT-dependent intraluminal vesicle formation. It links EGFR-activated RAB31 to flotillin-dependent vesicle formation and to reduced MVE–lysosome fusion, separating cargo packaging from the decision to secrete or degrade vesicles.
-
ONX-0914 (PR-957) in Immunoproteasome Research
2026-09-23
Use ONX-0914 (PR-957) to test how selective LMP7 inhibition changes immune signaling—but do not assume the effect is anti-inflammatory in every tissue. A 2025 airway study found that immunoproteasome inhibition increased IL-4Rα and worsened airway hyperresponsiveness, making tissue-specific controls essential.
-
15-PGDH Inhibition and Muscle Recovery with Semaglutide
2026-09-23
A 2026 PNAS study identifies 15-PGDH inhibition as a strategy to improve muscle stem cell activity, regenerated myofiber growth, and strength recovery during semaglutide-associated weight loss in obese mice. The work supports a preclinical combination approach that preserves semaglutide-mediated weight reduction while addressing impaired postinjury muscle regeneration.
-
LY294002 Workflows for PI3K Signaling
2026-09-22
Build clearer PI3K/Akt/mTOR experiments with LY294002 by combining dose-response design, pathway readouts, and controls for reversibility and off-target activity. The workflow also translates a microglial P2Y2 receptor study into practical assay choices without confusing its nucleotide-signaling findings with direct LY294002 evidence.
-
Birinapant (TL32711) Workflow for Apoptosis Studies
2026-09-22
Birinapant (TL32711) provides a mechanistic way to test whether IAP-dependent survival limits TNF, TRAIL, or chemoradiotherapy responses. This workflow connects cIAP1/2 degradation and caspase-8 activation with the MDM1–p53 findings reported in colorectal cancer, while clearly separating established evidence from testable experimental hypotheses.
-
RGFP966: Linking HDAC3 to HO-1 Activity
2026-09-21
RGFP966 provides a pharmacological route to investigate how HDAC3-associated regulation influences heme oxygenase-1 activity. This article explains how to pair the reagent with an activity-based fluorescent probe to separate changes in HMOX1 expression from changes in catalytic function and intracellular localization.
-
S Tag Peptide: Fusion Tag Workflow Guide
2026-09-21
S Tag Peptide is a 15-amino-acid RNase A-derived sequence used in genetically encoded fusions for recombinant protein detection, antibody-based capture, and protein solubility improvement. This guide covers construct design, reconstitution, QC, and troubleshooting while clarifying that the free peptide is not independently active and is unsuitable for ethanol-based systems or long-term solution storage.